FDCDDQ
NTLA icon

Federation des caisses Desjardins du Quebec’s Intellia Therapeutics NTLA Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.5K Hold
1,675
– – ﹤0.01% 2087
2025
Q4 		$15.1K Sell
1,675
-2,570
-61% -$35.4K ﹤0.01% 2132
2025
Q3 		$73.3K Sell
4,245
-506
-11% -$6.23K ﹤0.01% 1712
2025
Q2 		$44.6K Buy
4,751
+1,320
+38% +$10.8K ﹤0.01% 1582
2025
Q1 		$24.4K Buy
3,431
+1,500
+78% +$15.2K ﹤0.01% 1665
2024
Q4 		$22.5K Buy
1,931
+1,750
+967% +$27.3K ﹤0.01% 1643
2024
Q3 		$3.72K Hold
181
– – ﹤0.01% 2143
2024
Q2 		$4.05K Hold
181
– – ﹤0.01% 2004
2024
Q1 		$4.98K Hold
181
– – ﹤0.01% 1960
2023
Q4 		$5.52K Sell
181
-1,845
-91% -$53K ﹤0.01% 1888
2023
Q3 		$64.1K Hold
2,026
– – ﹤0.01% 1252
2023
Q2 		$82.6K Hold
2,026
– – ﹤0.01% 1207
2023
Q1 		$75.5K Buy
2,026
+6
+0.3% +$235 ﹤0.01% 1211
2022
Q4 		$70.5K Buy
2,020
+1,230
+156% +$58.5K ﹤0.01% 1361
2022
Q3 		$44.2K Buy
+790
New +$49K ﹤0.01% 1535
2018
Q3 		– Sell
-600
Closed -$16.4K – 2174
2018
Q2 		$16.4K Hold
600
– – ﹤0.01% 1618
2018
Q1 		$12.7K Sell
600
-50
-8% -$1.23K ﹤0.01% 1650
2017
Q4 		$12.5K Buy
+650
New +$15K ﹤0.01% 1666

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's NTLA Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec held its Intellia Therapeutics (NTLA) position steady in Q1 2026 at 1,675 shares worth $21.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2087.

Federation des caisses Desjardins du Quebec first reported a position in NTLA in Q4 2017 and has held it in 18 quarters since. The position peaked at $82.6K in Q2 2023. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Federation des caisses Desjardins du Quebec held 1,675 shares of Intellia Therapeutics worth $21.5K as of Q1 2026.
  • Federation des caisses Desjardins du Quebec left its Intellia Therapeutics share count unchanged in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q1 2026, its #2087 holding.
  • Federation des caisses Desjardins du Quebec first reported a position in Intellia Therapeutics in Q4 2017 and has held it in 18 quarters since.
  • Federation des caisses Desjardins du Quebec's Intellia Therapeutics position peaked at $82.6K in Q2 2023.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.